Because the pancreatic tumor mass of ductal adenocarcinoma most commonly arises from the head of the pancreas (and in areas adjacent to the head of the pancreas) which are the sections where the bile duct joins with the pancreatic duct, the normal flow of the bile duct is often obstructed, thus disrupting the natural deposition of the bile fluid (including its bile salts and pigments) into the small bowel. This bile duct obstruction causes a back-up of the bile pigment into areas where it shouldn’t normally go – creating the clinical symptoms of jaundice with its attendant yellowish skin coloration and other associated changes, and which is often accompanied by a loss of appetite (anorexia) and by the symptom of unrelenting and often debilitating pruritis (itching) of the skin.
Appropriate dosage of Prolixin Decanoate (Fluphenazine Decanoate Injection) should be individualized for each patient and responses carefully monitored. No precise formula can be given to convert to use of Prolixin Decanoate; however, a controlled multicentered study,* in patients receiving oral doses from 5 to 60 mg fluphenazine hydrochloride daily, showed that 20 mg fluphenazine hydrochloride daily was equivalent to 25 mg (1 mL) Prolixin Decanoate every three weeks. This represents an approximate conversion ratio of mL ( mg) of decanoate every three weeks for every 10 mg of fluphenazine hydrochloride daily.
In the 52-week double-blind phase of the placebo-controlled trial in which RISPERDAL® CONSTA® was administered as adjunctive therapy to patients with bipolar disorder in addition to continuing with their treatment as usual, approximately 4% (3/72) of RISPERDAL® CONSTA®-treated patients discontinued treatment due to an adverse event, compared with % (1/67) of placebo-treated patients. Adverse reactions associated with discontinuation in RISPERDAL® CONSTA®-treated patients were: hypokinesia (one patient) and tardive dyskinesia (one patient).